Generate Biomedicines (NASDAQ:GENB) Shares Gap Down – Should You Sell?

Generate Biomedicines Inc (NASDAQ:GENB)’s share price gapped down prior to trading on Monday . The stock had previously closed at $16.00, but opened at $15.25. Generate Biomedicines shares last traded at $13.7710, with a volume of 347,864 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Guggenheim started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $30.00 price target on the stock. Piper Sandler began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price objective for the company. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a research report on Wednesday, March 25th. Morgan Stanley raised their price target on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Finally, The Goldman Sachs Group initiated coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target for the company. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Generate Biomedicines Price Performance

The company’s 50 day simple moving average is $12.94.

Generate Biomedicines (NASDAQ:GENB) last announced its earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.